Abstract
Burkholderia mallei and Burkholderia pseudomallei are the causative micro-organisms of Glanders and Melioidosis, respectively. Although now rare in Western countries, both micro-organisms have recently gained much interest because of their unique potential as bioterrorism agents. This paper reviews the epidemiology, pathogenesis, diagnosis and treatment of Melioidosis and Glanders. Recent patents relating to these micro-organisms, especially potential vaccines, are presented. Continued research and development is urgently needed, especially in regard to rapid and accurate diagnosis of melioidosis and glanders, efficacious therapy and primary and secondary prevention.
Keywords: Melioidosis, glanders, burkholderia, bioterrorism
Recent Patents on Anti-Infective Drug Discovery
Title: Burkholderia mallei and Burkholderia pseudomallei: The Causative Micro-organisms of Glanders and Melioidosis
Volume: 2 Issue: 3
Author(s): Jacob Gilad
Affiliation:
Keywords: Melioidosis, glanders, burkholderia, bioterrorism
Abstract: Burkholderia mallei and Burkholderia pseudomallei are the causative micro-organisms of Glanders and Melioidosis, respectively. Although now rare in Western countries, both micro-organisms have recently gained much interest because of their unique potential as bioterrorism agents. This paper reviews the epidemiology, pathogenesis, diagnosis and treatment of Melioidosis and Glanders. Recent patents relating to these micro-organisms, especially potential vaccines, are presented. Continued research and development is urgently needed, especially in regard to rapid and accurate diagnosis of melioidosis and glanders, efficacious therapy and primary and secondary prevention.
Export Options
About this article
Cite this article as:
Gilad Jacob, Burkholderia mallei and Burkholderia pseudomallei: The Causative Micro-organisms of Glanders and Melioidosis, Recent Patents on Anti-Infective Drug Discovery 2007; 2 (3) . https://dx.doi.org/10.2174/157489107782497335
DOI https://dx.doi.org/10.2174/157489107782497335 |
Print ISSN 1574-891X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4071 |
Related Articles
-
Bisphenol A as a Factor in the Mosaic of Autoimmunity
Endocrine, Metabolic & Immune Disorders - Drug Targets New Perspectives of Infections in Cardiovascular Disease
Current Cardiology Reviews Colchicine, Biologic Agents and More for the Treatment of Familial Mediterranean Fever. The Old, the New, and the Rare
Current Medicinal Chemistry Cardiac Amyloidosis Responding to Bortezomib: Case Report and Review of Literature
Current Cardiology Reviews Rheumatoid Foot and Ankle Surgery
Current Rheumatology Reviews Lesson from the Pandemic: People should Always Stay Physically Active
Current Cardiology Reviews Mitochondrial MMP Activation, Dysfunction and Arrhythmogenesis in Hyperhomocysteinemia
Current Vascular Pharmacology The Relationship between Inflammatory and Oxidative Stress Biomarkers, Atherosclerosis and Rheumatic Diseases
Current Pharmaceutical Design Tissue Doppler Imaging: Beautiful Noise
Current Cardiology Reviews Traditional and Alternative Therapies for Refractory Angina
Current Pharmaceutical Design Henoch Schonlein Purpura in Childhood
Current Pediatric Reviews Cardiac Biomarkers in Acute Coronary Syndromes: A Review
Current Vascular Pharmacology Speculative Considerations about Some Cardiology Enigmas
Current Cardiology Reviews Frequency Domain Mapping of Atrial Fibrillation - Methodology, Experimental Data and Clinical Implications
Current Cardiology Reviews Surgical Treatment of Pulmonary Embolism and Chronic Thromboembolic Pulmonary Hypertension
Current Pharmaceutical Design Colchicine in Renal Diseases: Present and Future
Current Pharmaceutical Design Developing Histone Deacetylase Inhibitors as Anti-Cancer Therapeutics
Current Medicinal Chemistry Enterovirus D-68 Molecular Virology, Epidemiology, and Treatment: an Update and Way Forward
Infectious Disorders - Drug Targets Peptides Targeting Gap Junctional Structures
Current Pharmaceutical Design Autoimmune Fibrotic Adverse Reactions in One-Year Treatment with Cabergoline for Women with Prolactinoma
Endocrine, Metabolic & Immune Disorders - Drug Targets